Tandem Diabetes Care, Inc. (TNDM) Guidance & Earnings Results

On 2026-08-06 Tandem Diabetes Care, Inc. reaffirmed guidance: "FY2026 sales ~$1.065-1.085B; U.S. sales ~$730-745M; international sales ~$335-340M; gross margin ~56-57%; adjusted EBITDA margin ~5-6%; non-cash charges ~$85M (reduced from…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

TNDMTandem Diabetes Care, Inc.Follow TNDM — free

Medical Devices · Healthcare

—

Price chart with a free account

Market cap: 1.2B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 5 Nov, in 12 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
6 Aug 26	Reaffirmed	FY2026 sales ~$1.065-1.085B; U.S. sales ~$730-745M; international sales ~$335-340M; gross margin ~56-57%; adjusted EBITDA margin ~5-6%; non-cash charges ~$85M (reduced from $100M) · full year
7 May 26	Reaffirmed	FY2026 sales $1.065-1.085B; gross margin 56-57%; Adj. EBITDA margin 5-6% · full year
6 Nov 25	Reaffirmed	Sales ~$1.0B, gross margin 53-54%, Adj. EBITDA margin ~ -5% · full year
6 Aug 25	Reaffirmed	FY2025 sales ~$1.0B; U.S. sales ~$700M; international sales ~$300M (incl. $10M headwind); gross margin 53-54%; adjusted EBITDA margin recast to ~-5% from ~3% due to IPR&D charge reclassification; non-cash charges ~$115M (stock-based comp ~$95M, D&A ~$20M). · full year

Tandem Diabetes Care, Inc. — questions

What guidance did Tandem Diabetes Care, Inc. give?: On 2026-08-06: "FY2026 sales ~$1.065-1.085B; U.S. sales ~$730-745M; international sales ~$335-340M; gross margin ~56-57%; adjusted EBITDA margin ~5-6%; non-cash charges ~$85M (reduced from $100M)"
When does Tandem Diabetes Care, Inc. report earnings?: Tandem Diabetes Care, Inc.'s next earnings report is expected on 2026-11-05.

Every figure on this page comes from Tandem Diabetes Care, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.